Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc. (BCLI) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · BCLI · as of Sep 30, 2025
Ownership Breakdown
5
Institutional Holders
▼ 28 vs Q2
$1,727
Total Inst. Value
▼ $262,231 vs Q2
11.03M
Shares Outstanding
freeFloat 68.87%
2,317
13F Shares Held
▼ 233,461 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
BCLI largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
ADVISOR GROUP HOLDINGS, INC. biological products, (no diagnostic substances) | 1.8K | 2.07% | 2.07% | $1.35M | Nov 14, 2025 | — held |
BANGOR SAVINGS BANK biological products, (no diagnostic substances) | 266 | 0.31% | 0.31% | $188,000 | Oct 27, 2025 | — held |
VSM WEALTH ADVISORY, LLC biological products, (no diagnostic substances) | 120 | 0.14% | 0.14% | $85,000 | Nov 13, 2025 | — held |
STEWARD PARTNERS INVESTMENT ADVISORY, LLC biological products, (no diagnostic substances) | 113 | 0.13% | 0.13% | $80,000 | Nov 12, 2025 | — held |
ST GERMAIN D J CO INC biological products, (no diagnostic substances) | 33 | 0.04% | 0.04% | $23,000 | Oct 7, 2025 | — held |
JONES FINANCIAL COMPANIES LLLP biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Nov 4, 2025 | EXIT |
HARBOUR INVESTMENTS, INC. biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Nov 12, 2025 | EXIT |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Nov 7, 2025 | EXIT |
CLEARSTEAD ADVISORS, LLC biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Nov 10, 2025 | EXIT |
RAYMOND JAMES FINANCIAL INC biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Nov 14, 2025 | EXIT |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
0
Increased
+0 shares0
New Positions
first time holders0
Decreased
−0 shares28
Sold Out
fully exitedNet shares change (top 50)
+0
+0 / −0
Net new holders
-28
0 new / 28 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
BCLI insider trading · insider activity
Source: SEC Form 4
11
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Lebovits Chaim President & CEO | Feb 26, 2026 | Award | 1,800,000 | — | — | 2.00M | Form 4 ↗ |
Yablonka Uri EVP & Chief Business Officer | Feb 26, 2026 | Award | 150,000 | — | — | 218.5K | Form 4 ↗ |
Patlis Alla See Remarks | Feb 26, 2026 | Award | 100,000 | — | — | 144.3K | Form 4 ↗ |
FRENKEL JACOB A director | Feb 26, 2026 | Award | 200,000 | — | — | 243.8K | Form 4 ↗ |
ARBEL IRIT director | Feb 26, 2026 | Award | 120,000 | — | — | 161.1K | Form 4 ↗ |
Bairu Menghisteab director | Feb 26, 2026 | Award | 150,000 | $0.70 | $105.0K | 150.0K | Form 4 ↗ |
Polverino Anthony J. director | Feb 26, 2026 | Award | 150,000 | $0.70 | $105.0K | 150.0K | Form 4 ↗ |
HARTOUNIAN HARTOUN director | Feb 26, 2026 | Award | 225,000 | $0.70 | $157.5K | 225.0K | Form 4 ↗ |
Lindborg Stacy director | Feb 26, 2026 | Award | 150,000 | $0.70 | $105.0K | 150.0K | Form 4 ↗ |
Naor Nir director | Feb 26, 2026 | Award | 180,000 | $0.70 | $126.0K | 180.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Brainstorm Cell Therapeutics Inc. (BCLI) is primarily owned by institutional investors, who hold approximately 0.0% of total shares outstanding. Company insiders own approximately 31.13%, while retail and public investors account for the remaining 68.85%.
The largest institutional shareholder of Brainstorm Cell Therapeutics Inc. is ADVISOR GROUP HOLDINGS, INC., holding approximately 1,785 shares — equal to 2.07% of outstanding shares — as of September 30, 2025.
A total of 5 institutional investors currently hold BCLI stock, with a combined institutional value of approximately $1,727 as of the most recent 13F filing period.
Frequently asked questions
BCLI ownershipBrainstorm Cell Therapeutics Inc. (BCLI) is primarily owned by institutional investors, who hold approximately 0.0% of shares. The largest shareholder is ADVISOR GROUP HOLDINGS, INC. with a 2.07% stake. Company insiders hold 31.13%. Data sourced from SEC Form 13F as of September 30, 2025.